Using proteomics to advance the search for potential biomarkers for preeclampsia: A systematic review and meta-analysis

PLOS ONE, Apr 2019

Background Preeclampsia (PE) is a leading cause of maternal and perinatal morbidity and mortality worldwide. Although predictive multiparametric screening is being developed, it is not applicable to nulliparous women, and is not applied to low-risk women. As PE is considered a heterogenous disorder, it is unlikely that any single multiparametric screening protocol containing a small group of biomarkers could have the required accuracy to predict all PE subgroups. Given the etiology of PE is complex and not fully understood, it begs the question, whether the search for biomarkers based on the predominant view of impaired placentation involving factors predominately implicated in angiogenesis and inflammation, has been too limiting. Here we highlight the enormous potential of state-of-the-art, high-throughput proteomics, to provide a comprehensive and unbiased approach to biomarker identification. Methods and findings Our literature search identified 1336 articles; after review, 45 studies with proteomic data from PE women that were eligible for inclusion. From 710 proteins with altered abundance, we identified 13 common circulating proteins, some of which had not been previously considered as prospective biomarkers of PE. An additional search of the literature for original publications testing any of the 13 common proteins using non-proteomic techniques was also undertaken. Strikingly, 9 of these common proteins had been independently evaluated in PE studies as potential biomarkers. Conclusion This study highlights the potential of using high-throughput data sets, which are comprehensive and without bias, to identify a profile of proteins that may improve predictions of PE and understanding of its etiology. We bring to the attention of the medical and research communities that the strengths and advantages of using data from high-throughput studies for biomarker discovery would be increased dramatically, if first and second trimester samples were collected for proteomics, and if standardized guidelines for patient reporting and data collection were implemented.

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0214671&type=printable

Using proteomics to advance the search for potential biomarkers for preeclampsia: A systematic review and meta-analysis

April Using proteomics to advance the search for potential biomarkers for preeclampsia: A systematic review and meta-analysis Thy Pham Hoai NguyenID 0 1 Cameron James Patrick 1 Laura Jean Parry 0 1 Mary Familari 0 1 0 School of BioSciences, University of Melbourne , Parkville , Australia , 2 Statistical Consulting Centre, University of Melbourne , Parkville , Australia 1 Editor: Cassandra Nichole Spracklen, University of North Carolina at Chapel Hill , UNITED STATES Preeclampsia (PE) is a leading cause of maternal and perinatal morbidity and mortality worldwide. Although predictive multiparametric screening is being developed, it is not applicable to nulliparous women, and is not applied to low-risk women. As PE is considered a heterogenous disorder, it is unlikely that any single multiparametric screening protocol containing a small group of biomarkers could have the required accuracy to predict all PE subgroups. Given the etiology of PE is complex and not fully understood, it begs the question, whether the search for biomarkers based on the predominant view of impaired placentation involving factors predominately implicated in angiogenesis and inflammation, has been too limiting. Here we highlight the enormous potential of state-of-the-art, high-throughput proteomics, to provide a comprehensive and unbiased approach to biomarker identification. Our literature search identified 1336 articles; after review, 45 studies with proteomic data from PE women that were eligible for inclusion. From 710 proteins with altered abundance, we identified 13 common circulating proteins, some of which had not been previously considered as prospective biomarkers of PE. An additional search of the literature for original publications testing any of the 13 common proteins using non-proteomic techniques was also undertaken. Strikingly, 9 of these common proteins had been independently evaluated in PE studies as potential biomarkers. - Data Availability Statement: All relevant data are within the manuscript and its Supporting Information files. Funding: The author(s) received no specific funding for this work. Competing interests: The authors have declared that no competing interests exist. Abbreviations: EOPE, Early onset preeclampsia; FGR, fetal growth restriction; LOPE, late onset preeclampsia; NP, normal pregnant; PAPP-A, Background Methods and findings Conclusion This study highlights the potential of using high-throughput data sets, which are comprehensive and without bias, to identify a profile of proteins that may improve predictions of PE and understanding of its etiology. We bring to the attention of the medical and research communities that the strengths and advantages of using data from high-throughput studies for biomarker discovery would be increased dramatically, if first and second trimester samples pregnancy-associated plasma protein-A; PE, preeclampsia; PlGF, placental growth factor; sEng, soluble endoglin; sFlt-1, soluble fms-like tyrosine kinase-1; VEGF, vascular endothelial growth factor. were collected for proteomics, and if standardized guidelines for patient reporting and data collection were implemented. Introduction Preeclampsia (PE), described as a syndrome that affects 5?10% of all pregnancies, remains a leading cause of maternal and perinatal morbidity and mortality [ 1?3 ]. Although rare, PE can develop into eclampsia, which is responsible for over 50,000 maternal deaths globally per year [ 4 ]. Furthermore, PE is known to affect both the mother and child well beyond pregnancy and can lead to a higher risk of subsequent cardiovascular diseases later in life [ 5 ]. Currently, the American College of Obstetricians and Gynecologists (ACOG) [ 6 ], the International Society for the Study of Hypertension in Pregnancy [7] and the Society of Obstetric Medicine of Australia and New Zealand (SOMANZ) [8] characterize PE by the presence of new onset hypertension ( 140/90 mm Hg) after 20 weeks of gestation, accompanied by at least one end organ dysfunction (e.g. kidney, liver) or fetal growth restriction (FGR). This updated criterion reflects the growing awareness of the heterogeneity of the etiology of PE. Clinicians predominantly rely on PE risk factors including age (>35 years), previous PE or family history, multiple gestation, BMI (>25 kg/m2), ethnicity, and whether assisted reproductive techniques were involved, leading to classification of low or high risk [9]. However, clinical assessment of these risk factors has limited predictive ability [10,11] because it is not applicable to nulliparous women, and does not encompass all women who develop PE, particularly low risk women who are not monitored as frequently. This is underscored by a recent retrospective study in which 3,230 women, of those classified as low risk pregnancies (28.7% of 10 million women), unexpectedly developed eclampsia [12]. Thus, accurate screening for PE early in pregnancy remains a significant challenge. Alth (...truncated)


This is a preview of a remote PDF: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0214671&type=printable

Thy Pham Hoai Nguyen, Cameron James Patrick, Laura Jean Parry, Mary Familari. Using proteomics to advance the search for potential biomarkers for preeclampsia: A systematic review and meta-analysis, PLOS ONE, 2019, Volume 14, Issue 4, DOI: 10.1371/journal.pone.0214671